RT Journal Article
SR Electronic
T1 Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.12.20099879
DO 10.1101/2020.05.12.20099879
A1 Michael J. Joyner
A1 R. Scott Wright
A1 DeLisa Fairweather
A1 Jonathon W. Senefeld
A1 Katelyn A. Bruno
A1 Stephen A. Klassen
A1 Rickey E. Carter
A1 Allan M. Klompas
A1 Chad C. Wiggins
A1 John R.A. Shepherd
A1 Robert F. Rea
A1 Emily R. Whelan
A1 Andrew J. Clayburn
A1 Matthew R. Spiegel
A1 Patrick W. Johnson
A1 Elizabeth R. Lesser
A1 Sarah E. Baker
A1 Kathryn F. Larson
A1 Juan G. Ripoll
A1 Kylie J. Andersen
A1 David O. Hodge
A1 Katie L. Kunze
A1 Matthew R. Buras
A1 Matthew N.P. Vogt
A1 Vitaly Herasevich
A1 Joshua J. Dennis
A1 Riley J. Regimbal
A1 Philippe R. Bauer
A1 Janis E. Blair
A1 Camille M. Van Buskirk
A1 Jeffrey L. Winters
A1 James R. Stubbs
A1 Nigel S. Paneth
A1 Arturo Casadevall
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.12.20099879.abstract
AB Background Convalescent plasma is the only antibody based therapy currently available for COVID-19 patients. It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.Methods Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5,000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma.Results The incidence of all serious adverse events (SAEs) in the first four hours after transfusion was <1%, including mortality rate (0.3%). Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n=4), transfusion-associated circulatory overload (TACO; n=7), transfusion-related acute lung injury (TRALI; n=11), and severe allergic transfusion reactions (n=3). However, only 2 (of 36) SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The seven-day mortality rate was 14.9%.Conclusion Given the deadly nature of COVID-19 and the large population of critically-ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.Brief Summary After transfusion of COVID-19 convalescent plasma in 5,000 patients, the incidence of serious adverse events was <1% and the seven-day incidence of mortality was 14.9%.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04338360Funding StatementThis study was supported in part by a US Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) grant 75A50120C00096 (to MJJ), National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to JWS and CCW), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356 and R21 AI152318 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute RO1 HL059842 (to AC), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octopharma USA, Inc, and the Mayo Clinic.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available at this time. https://uscovidplasma.org